Reach Out to an Amgen Field Representative

Amgen Field Representatives are here to answer any questions you may have or to schedule a visit

To be connected to an Amgen Field Representative regarding product-related questions, complete the request below. To report an adverse event, please call 1‑800‑77‑AMGEN (1‑800‑772‑6436).

NPI number (optional)

Your NPI number will be used to automatically populate your name and address on the request form. This information will not be used for any other purpose.

Enter

*Required

*First Name *Last Name *Address 1 Address 2 Address 3 *City
*State
*ZIP Code
*Phone Number *Specialty
*Requestor’s Name *Would you like to be called back or visited at your office?
*Questions Related To

Amgen (and its contractors) will not sell or transfer the personal information you provide to us for this feature to any third parties. Information provided here will solely be used to connect you with an Amgen representative. More information on our privacy statement can be found here.

Important Safety Information

See More

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Allergic Reactions: Hypersensitivity reactions (e.g. angioedema, rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hyperlipidemia (including HeFH): The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52‐week trial and seven 12‐week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®‐treated and placebo‐treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.

Allergic reactions occurred in 5.1% and 4.7% of Repatha®‐treated and placebo‐treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new‐onset diabetes mellitus during the trial was 8.1% in patients assigned to Repatha® compared with 7.7% in those assigned to placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please see full Prescribing Information.

What is PCSK9?

Close X

Why Repatha® Inhibits PCSK9

Close X

How Repatha® Lowers LDL-C Levels

Close X

Using the Pushtronex® System

Close X

Using the SureClick® Autoinjector

Close X
Close X

CV Risk Remains: expert Perspectives

Close X
ISSUES IN CARDIOVASCULAR (CV) RISK MANAGEMENT

Gain expert insights on the risk of another MI or stroke in your CVD patients with Harold E. Bays, MD, and Seth J. Baum, MD.

CV Outcomes trial: expert Perspectives

Close X
the repatha® (evolocumab) cv outcomes trial (FOURIER)

Gain expert insights on the Repatha® CV Outcomes Trial (FOURIER) with Harold E. Bays, MD, and Seth J. Baum, MD.

repathaready® insurance support

Close X
RepathaReady® Insurance counselors support services for patients

Helping your patients navigate cost and coverage for Repatha® (evolocumab), counselors are available by phone at 1-844-REPATHA (1-844-737-2842), Monday–Friday, 9 AM–9 PM EST.

Close X

DR. SETH BAUM: Post-hoc Analysis in Patients With Prior MI

Close X

Clinical Challenges in Established Cardiovascular Disease: Second MI

Close X